Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Ex-US sub-licensees: commercialization and regulatory approval efforts outside the US
Indications
early-stage HER2-positive breast cancer (extended adjuvant)(Approved)
advanced/metastatic HER2-positive breast cancer(Approved)
Status note Marketed as NERLYNX: FDA-approved July 2017 for extended adjuvant treatment of early-stage HER2-overexpressed/amplified breast cancer following trastuzumab; February 2020 for advanced/metastatic HER2-positive breast cancer (with capecitabine); EC authorization 2018. Ongoing Phase 1 trial (NCT05372614, NCI-sponsored) of neratinib with fam-trastuzumab deruxtecan (ENHERTU).
Alisertib
Phase 2 · ActiveModality: small molecule (oral)
Target Aurora Kinase A
Partnerships Takeda: exclusive worldwide license for research, development and commercialization ($7M upfront October 2022; up to $287.3M milestones; tiered royalties)
Indications
extensive-stage small cell lung cancer (ALISCA-Lung1)(Phase 2)
breast cancer (ALISCA-Breast1)(Phase 2)
Status note Selective, reversible, ATP-competitive Aurora Kinase A inhibitor. ALISCA-Lung1 Phase 2 (monotherapy, extensive-stage SCLC) initiated February 2024; ALISCA-Breast1 Phase 2 initiated November 2024. Company intends to pursue alisertib initially in SCLC and hormone receptor-positive breast cancer.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 8 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.